Analysis of the inflammatory response in the rat paw caused by the venom of Apis melifera bee

Inflammation Research

Volumn 52, Issue 3, 2003, Pages 132-139

  Calixto, M C ^a   Triches K M ^a   Calixto, J B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Anti inflammatory drugs; Apis melifera; Bee venom; Inflammation; Leukocyte influx; Myeloperoxidase; Paw oedema

Indexed keywords

APAFANT; BEE VENOM; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ[8 LEUCINE 9 DEARGININE]; COMPOUND 48-80; COMPOUND 48/80; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYPROHEPTADINE; DEXAMETHASONE; HISTAMINE H1 RECEPTOR ANTAGONIST; ICATIBANT; INDOMETACIN; MEPYRAMINE; METHYSERGIDE; MYELOPEROXIDASE; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; N(G) NITROARGININE METHYL ESTER; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; OSANETANT; ROFECOXIB; SAREDUTANT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; VALERYL SALICYLATE;

ANALYSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HISTAMINE RELEASE; HONEYBEE; INFLAMMATION; LEUKOCYTE MIGRATION; MALE; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; PAW EDEMA; RAT; RAT STRAIN; SEROTONIN RELEASE; TIME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEE VENOMS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; ENZYME INHIBITORS; FOOT; HISTAMINE H1 ANTAGONISTS; INDICATORS AND REAGENTS; INFLAMMATION; INJECTIONS, SUBCUTANEOUS; MALE; NITRIC OXIDE SYNTHASE; PEROXIDASE; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; RECEPTORS, NEUROKININ-3; TIME FACTORS;

EID: 0037361992     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110300026     Document Type: Article

References (33)

1. Banks BEC, Shipolini RA. Chemistry and pharmacology of honey-bee venom. In: Venons of Hymenoptera, Academic Press Inc: London 1986, pp. 330-403.
2. Chen J, Luo C, Li H-L, Chen H-S. Primary hyperalgesia to mechanical and heat stimuli following subcutaneous bee venom injection into the plantar surface of hindpaw in the conscious rat: a comparative study with the formalin test. Pain 1999; 83: 67-76.
3. Chen J, Li L, Luo C, Li Z, Zheng JH. Involvement of peripheral NMDA and no-NMDA receptors in development of persistent firing of spinal wide-dynamic-range neurons induced by subcutaneous bee venom injection in the cat. Brain Res 1999; 844: 98-105.
4. Chen HS, Chen J, Chen J, Guo WG, Zheng MH. Establishment of bee venom-induced contralateral heat hyperalgesia in rat is dependent upon central temporal summation of afferent input from the site of injury. Neirosci Lett 2001; 298: 57-60.
5. Chen J, Chen HS. Pivotal role of capsaicin-sensitwe primary afferents in development of both heat and mechanical hyperalgesia induced by s.c. bee venom injection. Pain 2001; 91: 367-76.
6. Li KC, Zheng JH, Chen J. Involvement of spinal protein kinase C in induction and maintenance of both persistent spontaneous flicking reflex and contralateral heat hyperalgesia induced by subcutaneous bee venom in the conscious rat. Neurosci Lett 2000; 285: 103-6
7. Chen HS, Chen J, Sun YY. Contralateral heat hyperalgesia induced by unilaterally s.c. bee venom is produced by central changes: A behavioral study in the conscious rat. Neurosci Lett 2000; 284: 45-8.
8. Chen HS, Chen J. Secondary heat, but not mechanical hyperalgesia induced by subcutaneous injection of bee venom in conscious rat: effect of systemic MK-801, a non-competitive NMDA receptor antagonist. Eur J Pain 2000; 4: 389-401.
9. Zimennmman M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-10.
10. Martins MA, Pasquale CP, Silva PME, Cordeiro RS, Vargaftig BB. Eosinophil accumulation in the rat pleural cavity after mast cell stimulation with compound 48/80 involves protein synthesis and is selectively suppressed by dexamethasone. Int Arch Allergy Appl Immunol 1990; 92: 416-24.
11. 2 receptors in bradykinin-induced rat paw oedema. Br J Pharmacol 1995; 114: 1005-13.
12. Alves, RV, Campos, MM, Santos ARS, Calixto JB. Receptor subtypes involved in tachykinin-mediated edema formation. Peptides 1999; 20: 921-7.
13. 9-BK in rats pre-treated with LPS. Regulatory Peptides 2001; 89: 29-35.
14. Pinheiro R, Calixto JB. Effect of the selective COX-2 inibitors celecopxib and rofecoxib in rat acute models of inflammation. Inflamm Res 2003; 52: 132-9.
15. Souza DG, Coutinho SF, Silveira MR, Cara DC, Teixeira MM. Effect of a BLT receptor antagonist on local and remote reperfusion injuries after transient ischemia of the superior mesenteric artery in rats. Eur J Pharmacol 2000; 403: 121-8.
16. 1 receptor in rats. Br J Pharmacol 2002; 135: 1107-14.
17. Trebien HA, Calixto JB. Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. Agents Actions 1989; 26: 292-300.
18. Ajuebor MN, Singh A, Wallace JL. Ciclooxygenase-2 derived prostaglandin D-2 is an early anti-inflammatory signal an experimental colitis. Am J Physiol Gastrointest Liver Physiol 2000; 279: 238-44.
19. Di Rosa M, Giroud JP, Willoughby DA. Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J Pathol 1971; 104: 15-29.
20. Costa SKP, Esquisatto LCM, Camargo E, Gamberto A, Brain DS, De Nucci G et al. Comparative effect of Phoneutria nigriventer spider venom and capsaicin on the rat paw oedema. Life Sci 2001; 69: 1573-85.
21. Neves PC, Neves MC, Cruz AB, Sant'Ana AE, Yunes RA, Calixto JB. Differential effects of Mandevilla velutina compounds on paw oedema induced by phospholipase A2 and phospholipase C. Eur J Pharmacol 1993; 243: 213-9.
22. 9-BK-induced rat paw oedema by systemic treatment with bacterial endotoxin. Br J Pharmacol 1996; 117: 793-8.
23. 2 kinin receptors in oedema formation after long-term treatment with Mycobacterium bovis bacilus calmette-guérin (BCG). Br J Pharmacol 1997; 120: 502-8.
24. 1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor κB pathways. Br J Pharmacol 1999; 127: 1851-9.
25. Calixto JB, Cabrini DA, Ferreira J, Campos MM. Kinins in pain and inflammation. Pain 2000; 87: 1-5.
26. Calixto JB, Cabrini DA, Ferreira J, Campos MM. Inflammatory pain: kinins and antagonists. Current Opinion in Anesthesiol 2001; 14: 519-26.
27. Costa SK, Moreno RA, Esquisatto LC, Juliano L, Brain SD, De Nucci G et al. Role of kinins and sensory neurons in the pleural leukocyte migration induced by Phoneutria nigriventer spider venom. Neurosci Lett 2002; 318: 158-62.
28. Chan C-C, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflamamatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmal Exp Ther 1995; 274: 1531-7.
29. Chan C-C, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmcol Exp Ther 1999; 290: 551-60.
30. Dogan MD, Ataoglu H, Akarsu E. Effects of selective cycloxygenase enzyme inhibitors on lipopolysaccharide-induced dual thermoregulatory changes in rats. Brain Res Bull 2002; 57: 179-185.
31. Nantel F, Denis D, Gordon R, Northey A, Cirino M, Metters K et al. Distribuition and regulation of cyclooxygenase in carrageenan-induced inflammation. Br J Pharmacol 1999; 128: 853-9.
32. Franco-Penteado CF, De Souza, I, Texeira, SA, Ribeiro-DaSilva G, de Nucci G, Antunes E. Role of nitric oxide on the increased vascular permeability and neutrophil accumulation induced by staphylococcal enterotoxin B into the mouse paw. Biochem Phamacol 2001; 61: 1305-11.
33. Campos MM, Calixto JB. Neurokinin mediation of edema and inflammation. Neuropeptides 2000; 34: 314-22.